Printed From:


Select a patient type to see initial dosing information.

Weight-based dosing for insulin-naive patients starting Toujeo®
1/3 to 1/2 of the patient’s total daily dose (TDD) of insulin with Toujeo®
  • TDD = 0.2 to 0.4 Units/kg
  • Mealtime insulin should be used to satisfy the remainder of daily insulin requirements

0.2 Units/kg
unit conversion to start for patients with T1DM and T2DM switching to Toujeo®
80% of the total daily NPH dose to start for patients with T1DM and T2DM
Preview a copy of the Dosing Guide to download

Determine a starting dose for an insulin-naïve patient based on body weight1,a

T2DM Dosing Calculator

Enter a patient’s body weight—in pounds—to calculate the recommended starting dose of Toujeo®

T2DM, type 2 diabetes mellitus.

aUnits of Toujeo® are rounded down to the nearest whole unit and are calculated based on a recommended starting dose of 0.2 Units/kg. For dosing information in specific populations, please see the full Prescribing Information for Toujeo® . The appropriate starting dose in insulin-naive adults with type 1 diabetes mellitus (T1DM) is: kg x (0.2-0.4) = units.

The dosage of other antidiabetic drugs may need to be adjusted when starting Toujeo® to minimize the risk of hypoglycemia. View additional dosing information in the full Prescribing Information.


Set goals2

Per ADA, set titration goals
based on individualized
patient needsb

Individualize treatment1

Titrate according to
patient’s individualized
FPG goal

Adjust dose1

Titrate Toujeo® no more frequently
than every 3 to 4 days to minimize
the risk of hypoglycemia

  • The maximum glucose-lowering effect of Toujeo® may take up to 5 days to fully manifest in T1DM1
    • In T1DM, the first Toujeo® dose may be insufficient to cover metabolic needs in the first 24 hours
  • After changing from Lantus® to Toujeo®, patients may experience a temporary rise in fasting plasma glucose (FPG) in the first weeks of therapy1
  • In clinical trials, patients started on or changed to Toujeo® required a higher dose of basal insulin than patients controlled with Lantus®
icon Pen
Order samples to help get your patients started with Toujeo®

If prior authorization is required by a patient’s insurance plan, help is available. Access Sanofi Patient Connection™

bAmerican Diabetes Association (ADA) glycemic recommendations for fasting or premeal plasma glucose for nonpregnant adults with diabetes: 80-130 mg/dL. More or less stringent goals may be appropriate for individual patients.